Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (scIgG) (SCIGG-H201)

Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-BCMA and anti-TACI IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind two receptors simultaneously. It is designed for the research of Lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

BCMA & TACI

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

BCMA

Gene ID

608

UniProt ID

Q02223

Alternative Names

TNFRSF17; tumor necrosis factor receptor superfamily, member 17; BCM; BCMA; CD269; TNFRSF13A; tumor necrosis factor receptor superfamily member 17; B-cell maturation factor; B cell maturation antigen; B-cell maturation protein

Target 2

TACI

Gene ID

23495

UniProt ID

O14836

Alternative Names

TNFRSF13B; tumor necrosis factor receptor superfamily, member 13B; CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B; tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (scIgG) (SCIGG-H201). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (scIgG) (CAT#: SCIGG-H201)

Specifications

Targets

Customer Reviews and Q&As